Search bioRxiv⌕ Search

Biology subjects

Zieminska, A.

Publications and source records attributed to Zieminska, A..

2 recordsLinked to original sources

Highly diverged non-vertebrate Ki-67 proteins with conserved biophysical and functional properties

The Ki-67 protein is a widely used marker of mammalian cell proliferation that plays critical roles in heterochromatin organisation and mitotic perichromosomal layer formation. Thus, its apparent restriction to vertebrates is puzzling. However, sequences with limited homology to subdomains of Ki-67 are present in genomes from some non-vertebrate species. Here, using structural modelling, biophysical and functional analysis, we identify Ki-67-like proteins across diverse non-vertebrate eukaryotes, including tunicates, sponges, molluscs, insects and fungi. Despite extremely low sequence homology, the disordered domains of Ki-67 homologues have generally conserved biophysical and molecular properties. This is further reflected by comparison of cellular localisation, dynamics and effects on chromatin organisation of human, Ciona and Drosophila Ki-67 homologues. These results reinforce the emerging paradigm that functions may be encoded by general biophysical features in highly diverged intrinsically disordered domains. Our approach provides a blueprint for comparative biology of disordered proteins and a foundation for future studies exploring functions of Ki-67 homologues across eukaryotes.

Cell Biology↗

A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy

Chimeric antigen receptor T (CAR-T) cell therapy has shown extraordinary results in treating hematological cancer. However, many patients relapse because of heterogeneous antigen expression and outgrowth of antigen lost variants. Other problems include on-target-off-tumor toxicity and the requirement for manufacturing of complex cellular products. Universal and modular CAR constructs offer significantly improved flexibility, safety and cost-effectiveness over conventional CAR constructs. Here we present a new chimeric-antigen receptor (CAR)-fragment antibody binder (Fab) platform based on an engineered protein G variant (GA1) and Fab scaffolds that present exquisite specificity and selectivity on antibody capture. The expression of GA1CAR on human CD8+T cells leads to antigen recognition and T cell effector function that can be modulated according to the affinity of the CAR for the Fab scaffold and of the Fab for the target. GA1CAR-T cells can recognize multiple Fab-antigen pairs on breast and ovarian cancer cell lines. Adoptive transfer of GA1CAR-T cells/Fabs in breast cancer xenograft models leads to effective tumor control. Rapid re-direction of the CAR-T cells to a new target can be achieved by using different Fabs. GA1CAR expression confers favorable phenotypic properties to T cells including a higher effector function upon exposure to antigen as compared to conventional scFv CAR-T cells. This highly versatile "plug and play" CAR-T platform has potential for application in personalized therapy, preventing antigen loss variant escape, decreasing toxicity and increasing access.

bioengineering↗